Related Experiment Video

Updated: Aug 23, 2025

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
10:11

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

36.4K

Advances in the development of vaccines against Marburg and Ebola viruses

Peter L Collins1, Alexander Bukreyev2

  • 1Laboratory of Infectious Disease, National Institute of Allergy & Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MA 20892, USA.

Future Virology
|October 27, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.1K
Expression and Purification of Virus-like Particles for Vaccination06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.1K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
31.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
185